The Novel Coronavirus and Haemostatic abnormalities pathophysiology clinical manifesttations and treatment recommendations
Date
Authors
Susan Louw
Barry Jacobson
Elizabeth Mayne
Tracey Wiggill
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The COVID-19 pandemic, caused by the SARS-C0V-2 virus, was initially considered and managed in a similar manner to the previous SARS epidemic as they are both caused by coronaviruses. What has now become apparent is that a major cause of morbidity and mortality in COVID-19 is abnormal
thrombosis. This thrombosis occurs on a macro- and microvascular level and is unique to this disease. The virus has been demonstrated in the endothelium of the pulmonary alveoli and as such is thought to contribute to
the devastating respiratory complications encountered. D-dimer concentrations are frequently raised in COVID to levels not frequently seen previously. The optimal anticoagulation treatment in COVID remains
to be determined, and the myriad of pathophysiologic effects caused by this virus in the human host have also yet to be fully elucidated.
Description
Keywords
COVID-19, SARS-CoV-2, Coagulopathy, Thrombosis, Biomarkers, Treatment
Citation
Louw S, Jacobson BF, Mayne ES, Wiggill TM. The Novel Coronavirus and Haemostatic Abnormalities: Pathophysiology, Clinical Manifestations, and Treatment Recommendations. Adv Exp Med Biol. 2021;1321:173-180. doi:10.1007/978-3-030-59261-5_15